-transparent.png){kind=logo}
Sixteen patients with resistant non-Hodgkin's lymphoma were treated with continuous infusions of vincristine (1-2 mg/m2 daily X 2 days) and bleomycin (0.25 mg/kg bolus dose, then 0.25 mg/kg/daily X 5 days). Responding patients received high dose methotrexate (1500 mg/m2) with citrovorum rescue on days 15, 22, 29, 36. Treatment cycles were repeated every six weeks in responding patients. The response frequency was 50% (three complete and five partial responses). Median response duration was 29 weeks. Major toxicity included stomatitis (63%) and leukopenia (44%). One episode each of possible hypersensitivity pneumonitis and paralytic ileus occurred. Continuous infusions of vincristine and bleomycin should be studied further in less critically ill patients.
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
April 1982,
Cancer,
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
April 1987,
American journal of clinical oncology,
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
March 1989,
Indian journal of cancer,
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
May 1975,
European journal of cancer,
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
June 1984,
Cancer,
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
January 1989,
Selective cancer therapeutics,
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
January 1984,
Medical and pediatric oncology,
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
August 1992,
International journal of hematology,
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
January 1986,
Pediatric hematology and oncology,
D Hollister, and
R T Silver, and
B Gordon, and
M Coleman
December 1983,
Gan to kagaku ryoho. Cancer & chemotherapy,
